Apellis Pharmaceuticals, Inc. (APLS)
| Market Cap | 5.25B +138.6% |
| Revenue (ttm) | 1.11B +42.5% |
| Net Income | 133.27M |
| EPS | 1.03 |
| Shares Out | 128.02M |
| PE Ratio | 39.98 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,067,415 |
| Open | 41.02 |
| Previous Close | 41.01 |
| Day's Range | 41.00 - 41.05 |
| 52-Week Range | 16.10 - 41.14 |
| Beta | -0.25 |
| Analysts | Hold |
| Price Target | 35.53 (-13.4%) |
| Earnings Date | May 7, 2026 |
About APLS
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glome... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for APLS stock is "Hold." The 12-month stock price target is $35.53, which is a decrease of -13.40% from the latest price.
News
Remitly Global to replace Apellis in S&P 600 at open on 5/14
Remitly Global (RELY) will replace Apellis Pharmaceuticals (APLS). S&P 500 constituent Biogen (BIIB) is acquiring Apellis Pharmaceuticals in a deal expected to close soon, pending final closing condit...
Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600
NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Famil...
Wells Fargo downgrades Apellis to Equal Weight following Biogen’s acquisition
As previously reported, Wells Fargo analyst Derek Archila downgraded Apellis (APLS) to Equal Weight from Overweight with a price target of $41, up from $26. The firm is moving to
Apellis downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo downgraded Apellis (APLS) to Equal Weight from Overweight with a price target of $41, up from $26.
Apellis price target raised to $41 from $21 at RBC Capital
RBC Capital analyst Lisa Walter raised the firm’s price target on Apellis (APLS) to $41 from $21 and keeps a Sector Perform rating on the shares as part of the
Apellis price target raised to $41 from $20 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Apellis (APLS) to $41 from $20 and keeps a Neutral rating on the shares. The firm cites the announced acquisition
Apellis downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Adam Walsh downgraded Apellis (APLS) to Neutral from Buy with a price target of $41, up from $31, following Biogen’s (BIIB) announced acquisition at $41 per share
Biogen price target raised to $275 from $250 at Oppenheimer
Oppenheimer raised the firm’s price target on Biogen to $275 from $250 and keeps an Outperform rating on the shares. The firm believes Biogen’s (BIIB) acquisition of Apellis (APLS) for
Apellis downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao downgraded Apellis (APLS) to Neutral from Buy with a price target of $41, down from $48, to reflect the pending acquisition by Biogen (BIIB). Published
Apellis downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Anupam Rama downgraded Apellis (APLS) to Neutral from Overweight with a price target of $41, up from $37, after the company entered into an agreement to be acquired
Apellis downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Ryan Deschner downgraded Apellis (APLS) to Market Perform from Outperform without a price target after the company entered into an agreement to be acquired by Biogen (BIIB)
Apellis downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald downgraded Apellis (APLS) to Neutral from Overweight without a price target after the company entered into an agreement to be acquired by Biogen (BIIB) for $41.00 per share
Apellis downgraded to Hold from Buy at Stifel
Stifel analyst Annabel Samimy downgraded Apellis (APLS) to Hold from Buy with a $41 price target after news that Biogen (BIIB) is acquiring the company for $5.6B in cash up
Apellis downgraded to Neutral from Buy at Citi
Citi analyst Yigal Nochomovitz downgraded Apellis (APLS) to Neutral from Buy with a price target of $41, down from $44, after the company agreed to be acquired by Biogen (BIIB).
Apellis downgraded to Hold from Buy at Jefferies
Jefferies downgraded Apellis (APLS) to Hold from Buy with a price target of $41, down from $55, after news that Biogen (BIIB) is acquiring the company for $5.6B in cash
Why This Pharma Stock More Than Doubled Today
A small biopharmaceutical firm was getting a big boost Tuesday after Biogen agreed to buy it for $5.6 billion.
Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases
Biogen, already developing a drug that can be used to treat several kidney disorders, is paying a large premium for Apellis Pharmaceuticals
Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion
Biogen agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, expanding its portfolio in immunology and rare-disease medicines.
Biogen to buy Apellis Pharmaceuticals for $5.6 billion
Biogen said on Tuesday it has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash.
Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology.
CAMBRIDGE, Mass. and WALTHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced the companies have entered into a de...
Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
CAMBRIDGE, Mass. and WALTHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced the companies have entered into a de...
Apellis Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing three strategic pillars: SYFOVRE for geographic atrophy, EMPAVELI for rare kidney diseases, and a gene editing program, with strong early launch momentum and robust pipeline innovation. Despite a revenue dip from co-pay disruptions, underlying demand and market share remain strong, and the company is well-capitalized for future growth.
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D.
Apellis Pharmaceuticals Earnings Call Transcript: Q4 2025
Steady commercial execution in 2025 drove strong pipeline progress and resilient demand for Syfovre and Empaveli, with robust financials and a stable outlook for 2026. Key innovations and clinical data support long-term growth and market leadership.
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its fourth quarter and full year 2025 financial results and business highlights.